Qstent
Pre-clinical- Indications
- Vascular disease
Company intelligence / Profile preview
Qvanteq
Zurich, Zurich, Switzerlandqvanteq.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Qvanteq has developed a proprietary antithrombotic biofunctional surface platform ("Qstent") designed to reduce thrombus formation and inflammatory response in vascular stents. The company claims this leads to faster healing compared to conventional technologies. No published clinical trial results are referenced in the available sources.
- Therapeutic areas
- Cardiovascular
- Modalities
- DeviceSurface modification technology
- Industry
- Implantable Medical Devices
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Qvanteq.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qvanteq.